The raised revenue guidance and improved expense outlook are credit-positive signals, but the sharp YoY revenue decline and continued net loss keep the stock range-bound near-term. Monitor for Sanofi's CIC trial initiation (a $125M catalyst) and the mid-2027 tech transfer milestone ($75M) as the next major value-inflection events.
Price Chart
Executive Summary
Novavax reported Q2 2026 total revenue of $57M, a 76% decline YoY from $239M, driven by the absence of a $175M BLA milestone and $27M Takeda amendment that benefited the prior year. The company posted a GAAP net loss of $53M ($-0.32 per share) versus net income of $107M in Q2 2025. However, Novavax raised its full-year 2026 Adjusted Total Revenue framework to $235M-$275M (from $230M-$270M) and improved GAAP combined R&D and SG&A expense guidance, signaling confidence in its partnership-driven strategy and cost discipline despite the quarterly revenue drop.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue was $57M, down 76% YoY from $239M.
- GAAP net loss of $53M ($-0.32 per share) vs net income of $107M ($0.66) in Q2 2025.
- EPS of $-0.32 beat consensus of $-0.38 by 16.6%.
- Raised full-year 2026 Adjusted Total Revenue guidance to $235M-$275M from $230M-$270M.
- Improved GAAP combined R&D and SG&A expense guidance to $370M-$410M from $380M-$420M.
- Cash, equivalents, and marketable securities were $724M as of June 30, 2026.
- Sanofi confirmed advanced discussions with regulators for Phase 3 COVID-19-Influenza Combination trial; initiation would trigger a $125M milestone.
- Manufacturing tech transfer to Sanofi expected mid-2027, triggering a $75M milestone.
Financial Impact
Q2 2026 revenue of $57M (76% YoY decline); net loss of $53M vs net income of $107M in Q2 2025; raised FY2026 revenue guidance by $5M at midpoint to $235M-$275M.
Risk Factors
- Dependence on Sanofi partnership for future revenue and milestones; any delays in CIC trial or tech transfer would push catalysts out.
- Continued net losses and negative stockholders' deficit of $190.7M raise long-term capital concerns despite current cash runway.
- COVID-19 vaccine demand remains seasonal and unpredictable, limiting visibility on Nuvaxovid product sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001000694-26-000019 |
| Document: prfinal.htm | 0001000694-26-000019 |
| Document: 0001000694-26-000019-index-headers.html | 0001000694-26-000019 |
| Document: 0001000694-26-000019-index.html | 0001000694-26-000019 |
| Document: 0001000694-26-000019.txt | 0001000694-26-000019 |
| 8-K Data (Synthetic) | 0001000694-26-000019 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $7.74 $10.34 | ▲ +33.59% | ▲ +32.99% | $10.35 (+33.79%) |
May 6, 2026 21w ago | 8-K | $9.36 $10.20 | ▲ +8.97% | ▲ +6.19% | $10.35 (+10.63%) |
Apr 27, 2026 22w ago | DEFA14A | $8.07 $10.46 | ▲ +29.62% | ▲ +24.66% | $10.35 (+28.31%) |
Feb 26, 2026 31w ago | 8-K | $11.19 $8.95 | ▼ −20.02% | ▼ −13.62% | $10.35 (−7.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access